Objective: A prospective observational study was conducted to test the agreement between 2 commercially available automated cardiac troponin-I immunoassay systems (Opus Plus, Behring Diagnostics UK Ltd, Hounslow, UK; Ax-SYM, Abbott Laboratories, Abbott Park, IL) and to determine a normal reference range and threshold value indicative of perioperative myocardial infarction (PMI) after elective coronary artery bypass graft (CABG) surgery for the Opus Plus system.Design: Prospective, observational study. Setting: Single institution, cardiothoracic specialty hospital.Participants: Seventy patients undergoing elective CABG surgery.Interventions: After institutional review board approval, patients received standardized anesthetic, surgical, and myocardial preservation techniques. Serial electrocardiographs, creatine kinase-MB, troponin-I, and perioperative outcome data were collected. Correlation between the immunoassay systems was tested using 124 duplicate samples from the first 18 patients. The normal reference range and threshold value indicative of PMI were tested for the Opus Plus system using duplicate samples from all 70 patients. There was clear proportional bias that was corrected with log transformation of the raw data. By using confidence interval and receiver operating characteristic curve analysis, the authors showed that a value >15 g/L was indicative of PMI (Opus Plus system) and accordingly report a 35.7% (2.9% Q-wave) overall incidence of PMI in this study population (n ؍ 70).
Measurements and MainConclusions: These data highlight differences between commercially available troponin-I assay systems. The authors recommend that each institution establish a local reference range and threshold indicative of perioperative myocardial infarction for its specific patient population and assay system and provide sample methodology. © 2005 Elsevier Inc. All rights reserved.KEY WORDS: coronary artery bypass graft surgery, perioperative myocardial infarction, troponin-I, receiver operating characteristic curve analysis D ESPITE ADVANCES IN myocardial protective strategies, ischemic injury often complicates coronary artery bypass graft (CABG) surgery. Accurate diagnosis and timely intervention of perioperative myocardial infarction (PMI) are vital because major ischemic injury is associated with reduced hospital 1-4 and long-term 5,6 survival. Similarly, more recent data suggest that minor ischemic injury after CABG surgery is also associated with adverse short-term 7,8 and medium-term 9 outcome. Accurate assessment of ischemic injury will facilitate the comparison and optimization of myocardial protective strategies with further improved surgical outcome.The Joint European Society of Cardiology/American College of Cardiology Committee for redefinition of myocardial infarction (MI) currently considers cardiac troponin isozyme (cTn) as the biomarker of choice for myocardial injury. 10 This is on account of the improved sensitivity and specificity of cTn for acute MI, both nonsurgical 11,12 and perioperative 7,13-1...